Abstract:Biological products for treatment of rheumatoid arthritis usually are cost effective for healthcare systems in Europe, but they are huge financial burden due to the high number of patients and the significant budget impact. The expected saving from introduction on the market of biosimilars are significant and are linked to better access and affordability. The aim of this study was to conduct comparative price analysis of biological products for rheumatoid arthritis therapy among seventeen EU countries. The point of view is that of the Bulgarian pricing and reimbursement system and the chosen countries are those from external reference basket for prices comparison at manufacturing level. All authorized biological products by EMA with therapeutic indication rheumatoid arthritis were selected. The access for treatment is evaluated as the availability of the product on the market and the prices level. We assessed the availability of all trade names in the price lists of the observed countries. The prices data was obtained from the official web pages of the responsible institutions up to date December 2017. The results show that four out of all six INNs have authorized biosimilars in EMA. Despite its earlier authorization biosimilar adalimumab is not present in any of the price lists of countries. From all eighteen countries only in Lithuania and Estonia there were no published prices of any of the selected medicinal products. Countries with higher number of biosimilar prices are Spain and France. Differences in manufacturers' prices of reference biological products in selected countries in comparison with the lowest manufacturer price are higher with 22 to 69% while the retail prices between 62 and 95%. Differences are mostly notable for rituximab, and less notable for tocilizumab. Manufacturers' and retail prices of biosimilar products were established only for three INNs (etanercept, rituximab, and infliximab). Manufacturers' prices differ between 26 and 75%, while retail prices differ between 40 and 92% for biosimilars. Comparison of the differences between manufacturer prices of reference biological product and biosimilars shows 36% difference for etanercept, 39% for rituximab, and 31% for infliximab, while at retail level the differences are 11, 86, and 143%, respectively. The limitation of the study is that the prices are the official ones without discounts due to confidentiality and the real prices may be lower. The second limitation is that the methodology for pricing differs in the countries and this could also influence the prices on both levels (manufacturer and retail). Introduction of biosimilars on the national markets led to significant decrease in reimbursed prices paid by public funds and thus might benefit the patients' access to biological therapy. The decrease of prices after biosimilars entrance on the market is not as notable as for commodity generics.

A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy

Comparative price analysis of biological medicines: disparities generated by different pricing policies

Learnings from cross-border biosimilar pricing policies in Europe

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

The Biosimilar Revolution: Assessing the European Union's Approach to Biosimilarity, Interchangeability, Patient Access, and Its Market Analysis

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare

Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review

Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study

Biosimilars and access to biologic therapy in immune-mediated diseases

Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues

Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

A Regulatory Perspective on Biosimilar Medicines

Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America

Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology

Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

The economics of translating a biosimilar from lab to market in India

Short and long-term economic implications of biosimilars